Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018
February 26 2018 - 7:00AM
Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage
biotechnology company developing novel hospital-based therapies in
the management of acute, life-threatening conditions, today
announced it will host a conference call on Thursday, March 1, 2018
at 8:30 a.m. ET to discuss its fourth quarter and full year 2017
financial results.
The conference call will be available via phone and webcast. To
access the call, please dial (877) 388-5691, or (562) 350-0788 for
international callers, and reference conference ID 4891539
approximately 15 minutes prior to the call.
A replay of the call may be accessed through March 15, 2018 on
the investor section of Edge’s website or by dialing (855)
859-2056, or (404) 537-3406 for international callers, and
referencing conference ID 4891539. A live webcast of the conference
call will be available on the investor relations section of Edge’s
web site at www.edgetherapeutics.com.
About Edge Therapeutics, Inc.Edge Therapeutics,
Inc. is a clinical-stage biotechnology company that discovers,
develops and seeks to commercialize novel, hospital-based therapies
capable of transforming treatment paradigms for the management of
acute, life-threatening neurological and other conditions. EG-1962,
Edge’s lead product candidate, has the potential to fundamentally
improve patient outcomes and transform the management of aneurysmal
subarachnoid hemorrhage, which is bleeding around the brain due to
a ruptured brain aneurysm. Edge is evaluating EG-1962 in two
clinical studies: a pivotal Phase 3 NEWTON 2 study of EG-1962
delivered via EVD, and a study of direct intracisternal
administration of EG-1962. For additional information about Edge,
please visit www.edgetherapeutics.com.
Forward-Looking StatementsThis press release
and any statements of representatives of Edge Therapeutics, Inc.
related thereto that are not historical in nature contain, or may
contain, among other things, certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, without
limitation, statements with respect to Edge’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as "projects," "may," "will," "could,"
"would," "should," "believes," "expects," "anticipates,"
"estimates," “seeks,” "intends," "plans," "potential" or similar
expressions, including statements with respect to Edge’s future
clinical plans, Edge’s ability to advance its portfolio of
therapies towards commercialization and the potential effects of
its products. These statements are based upon the current beliefs
and expectations of Edge’s management and are subject to
significant risks and uncertainties. Actual results may differ
significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks
and uncertainties that are subject to change based on various risk
factors (many of which are beyond Edge's control) as described
under the heading "Risk Factors" in Edge’s filings with the United
States Securities and Exchange Commission.
Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: ir@edgetherapeutics.com
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jul 2023 to Jul 2024